Skip to main content

Cardio/Pulmonary

stop.smoking.jpg

Rheumatoid Arthritis Patients Need to Quit Smoking ASAP

Oct 04, 2022

While it is known that smoking ups the risk of developing RA, its effect on outcomes in those with established rheumatoid arthritis (RA) is less known.  A report from an early arthritis registry shows that current smoking increases disease activity and lowers health-related quality of life.

Read Article
NSAIDs.pills_.caps_.jpg

NSAIDs Linked to Heart Failure in Diabetes Patients

EurekAlert!
Sep 27, 2022

Short-term use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a first-time hospitalisation for heart failure in patients with type 2 diabetes, according to research presented at ESC Congress 2022.

Read Article
RheumNow Podcast square

Heavy Metal Rheumatology (9.23.2022)

Sep 23, 2022

Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website

Read Article
antibody (Keep)

Clinical Profiles Seen with NXP-2 Antibodies

Sep 20, 2022

A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer.

Read Article
cardiac2.jpg (keep)

Gout Comes With Increased Heart Risk

MedPage Today
Sep 13, 2022

Incidence of acute coronary syndrome (ACS) was significantly higher among gout patients than in the general Swedish population, researchers found, even when data were adjusted for common comorbidities.



First-time ACS was diagnosed at a rate of 9.1 per 1,000 person-years in a cohort of

Read Article
IPF.lancet.jpg

Pirfenidone Potential in RA-Related Lung Disease

MedPage Today
Sep 07, 2022

Rheumatoid arthritis patients with existing interstitial lung disease (ILD) had less decline in lung function when receiving the antifibrotic agent pirfenidone (Esbriet) relative to placebo in a randomized trial, researchers reported here and in a simultaneous journal publication.

Read Article
heart,cv,meds, events, CVD

Study Reassures on HCQ Heart Risks in Rheumatoid Arthritis

MedPage Today
Sep 06, 2022

Among U.S. veterans receiving hydroxychloroquine (HCQ) as long-term therapy for rheumatoid arthritis, development of long QT syndrome was rare and not markedly more common compared with similar patients treated with other agents, researchers said.

Read Article
RheumNow Podcast square

Goofy But True

Sep 02, 2022

Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.com.




  1. After historic drop in 2020 (COVID), life expectancy in USA dropped again,

Read Article
myositis, polymyositis, wikipedia

EULAR/ACR Classification in MDA5+ Myositis Patients

The diagnosis of idiopathic inflammatory myopathies (IIMs) can be informed by the 2017 EULAR/ACR classification criteria, but their utility in patients with clinically amyopathic dermatomyositis (CADM) and anti–melanoma differentiation–associated protein 5 (anti–MDA-5)–positive IIM is less

Read Article
heart.EKG_.CVD_.jpg

Autoimmune Disease Augments Cardiovascular Risk

Aug 29, 2022

A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.



A population-based study examined 22,009,375 persons from the Clinical Practice Research Datalink (CPRD), GOLD and Aurum datasets.  This included

Read Article
PSS.scleroderma.arthritis.contractures

Rituximab Efficacy in Systemic Sclerosis

Aug 18, 2022

The DESIRES trial studied rituximab (RTX) in patients with systemic sclerosis (SSc) and showed clinically significant improvement in skin and lung outcomes after a subsequent 24-week open-label extension phase.

Read Article
RheumNow Podcast square

Hit Parade Review (8.12.2022)

Aug 12, 2022

We've got a lot to discuss this week: psoriasis; fatigue; sleep; sural nerve biopsies; uveitis and SpA; diet and RA; tofacitinib and the ORAL surveillance study; what not to take with mycophenolate - and more. In what order should these items be discussed? This week the run down is based on

Read Article
morbidity,covid,heart,lung,brain

Arthritis - a Leading Chronic Condition Among Young Adults (18─34 Yrs)

Aug 11, 2022

MMWR from last week focused on chronic conditions in young adults showing they are common, costly, and major causes of death and disability. Overall arthritis ranks behind five more common chronic condition in young adults - obesity, depression, hypertension, hypercholesterolemia and asthma

Read Article
Clot.DVT_.VTE_.blood_.jpg

Cytomegalovirus Increases Thromboembolism Risk in ANCA-associated Vasculitis

Aug 11, 2022

Infection may play an important role in the genesis of vasculitis and ANCA seropositivity; this report suggests that past cytomegalovirus infection may be a risk in the occurrence of venous thromboembolism (VTE) in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. 

Read Article
RheumNow Podcast square

The Great Unknowns (8.5.2022)

Aug 05, 2022

Dr. Jack Cush reviews the news, FDA approvals, journal articles from the past week on RheumNow; plus viewer questions. This week great hopes for vitamin D, the great unknows of CSA and the great big mess that is the gout.




  1. 521 clinically suspect arthralgia (CSA) pts were

Read Article
CV,risk,MI,heart,cardiac

Gout Flares Up Cardiac Risks

Aug 03, 2022

A large case-control study showed that gout patients who experienced a cardiovascular (CV) event were more likely to have had a recent (< 120 days) gout flare compared to those without CV events.



This study sought to investigate the temporal association between gout flares and

Read Article
Lungs ILD

Approach to ILD in Myositis Syndromes

Jul 28, 2022

Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.



They divide myositis-ILD into three main prognostic

Read Article
IPF.JPG

Nintedinib’s Durable Efficacy in Systemic Sclerosis

MedPage Today
Jul 26, 2022

Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said.



Among participants who remained on the drug until the protocol had them stop,

Read Article
2021,year

ICYMI: 2021 Rheumatology Year in Review

Jul 08, 2022

For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
RheumNow Podcast square

What Worries You, Masters You (7.1.2022)

Jul 01, 2022

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com.  Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.




  1. FDA approved Abbvies risakizumab-rzaa

Read Article
heart,cv,meds, events, CVD

HCQ for RA: Not a Great Idea?

MedPage Today
Jun 28, 2022

Hydroxychloroquine (HCQ) appeared less safe from a cardiovascular standpoint than methotrexate in older patients with rheumatoid arthritis (RA), analysis of Medicare data indicated.



Among RA patients 65 and older with a history of heart failure, major cardiovascular events occurred

Read Article
It's time to exonerate methotrexate in causing or exacerbating fibrotic interstitial lung disease in #RA patients https://t.co/AuEIWn8Pc4 https://t.co/razVTF6fFX
450 axSpA pts followed 2868 Pt-yrs, 48% on TNFis. TNFi Rx pts had reduced CV risk (HR 0.30; 0.10–0.85), but no longer signif after adjustment for CRP, ESR (HR 0.37, 0.12–1.12, p = 0.077). Reduced CV risk, may not be specifically due to TNFi use https://t.co/mVHYn3PteL https://t.co/bgKWreBL8z
CV risk factors not equal when considering magnitude of risk What can we learn from Oral Surveillance? The Oral Surveillance trial has almost become a household word for rheumatologists.https://t.co/LHZTVZh4AK https://t.co/2SlxrG7UpQ
heart.jpg (keep)

CV risk factors not equal when considering magnitude of risk

What can we learn from Oral Surveillance?



The Oral Surveillance trial has almost become a household word for rheumatologists.



To recap, it was an FDA-mandated, open-label, randomized controlled trial that had high CV risk patients with active RA, on background stable dose

Read Article
×